Active substance |
Midostaurin (PKC412) soft gelatin capsules of 25 mg |
Holder |
Novartis Pharma |
Status |
Running |
Indication |
Treatment of adult, newly diagnosed FLT3 mutated acute myeloid leukemia patients eligible for standard induction and consolidation chemotherapy. |
Public documents |
|
Last update |
30/06/2016 |
Midostaurin®
Last updated on 13/02/2024